Joseph R. Young

Joseph R. Young

Auto-generated profile, based on publicly available information

Joseph R. Young

Division of Orthopaedic Surgery, Albany Medical Center, Albany, New York

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2015 in Circulation
Verified
Journal Article
Closed access
PAPankaj Arora
Pankaj Arora
YSYanna Song
Yanna Song
JDJeffery Dusek
Jeffery Dusek
GPGregory Plotnikoff
Gregory Plotnikoff
MSMarc S. Sabatine
Marc S. Sabatine
TWThomas J. Wang
Thomas J. Wang
Background—: A large body of epidemiological and experimental evidence suggests that vitamin D deficiency may promote hypertension. This raises the possibility that vitamin D supplementation could be a simple intervention to reduce blood pressure, but data from prospective, randomized trials are limited. Methods and Results—: A double-blind, randomized, controlled trial was conducted at 4 sites in the United States. We enrolled 534 individuals 18 to 50 years of age with low vitamin D status (25-hydroxyvitamin D levels ≤25 ng/mL) and systolic blood pressure of 120 to 159 mm Hg. Participants were randomized to high-dose (4000 IU/d) versus low-dose (400 IU/d) oral vitamin D 3 for 6 months. The primary end point was change in mean 24-hour systolic blood pressure. Secondary end points included change in ambulatory diastolic blood pressure and clinic systolic and diastolic blood pressures. The median age was 38 years, and 62% of participants were men. Forty-six percent of participants were white, and 48% were black. The median 25-hydroxyvitamin D level at baseline was 15.3 ng/mL. Four-hundred fifty-five participants (85%) had at least 1 follow-up blood pressure measurement; 383 participants (72%) completed the full 6-month study. At the end of the study, there was no significant difference in the primary end point (change in mean 24-hour systolic blood pressure, −0.8 versus −1.6 mm Hg in the high-dose and low-dose arms; P =0.71) or in any of the secondary end points. Furthermore, there was no evidence of association between change in 25-hydroxyvitamin D and change in 24-hour systolic blood pressure at 6 months (Spearman correlation coefficient, −0.05, P =0.34). Results were consistent across prespecified subgroups. Conclusions—: Vitamin D supplementation did not reduce blood pressure in individuals with prehypertension or stage I hypertension and vitamin D deficiency. Our findings suggest that the association between vitamin D status and elevated blood pressure noted in observational studies is not causal. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01240512.

1 December 2018 in Orthopedic Research and Reviews
Verified
Journal Article
Open access
PDF file
JYJoseph R Young
Joseph R Young
SSSarah Sternbach
Sarah Sternbach
MWMax Willinger
Max Willinger
IHIan D Hutchinson
Ian D Hutchinson
ARAndrew J. Rosenbaum
Andrew J. Rosenbaum
Plantar fibromatosis (Ledderhose disease) is a rare, benign, hyperproliferative fibrous tissue disorder resulting in the formation of nodules along the plantar fascia. This condition can be locally aggressive, and often results in pain, functional disability, and decreased quality of life. Diagnosis is primarily clinical, but MRI and ultrasound are useful confirmatory adjuncts. Given the benign nature of this condition, treatment has historically involved symptomatic management. A multitude of conservative treatment strategies supported by varying levels of evidence have been described mostly in small-scale trials. These therapies include steroid injections, verapamil, radiation therapy, extracorporeal shock wave therapy, tamoxifen, and collagenase. When conservative measures fail, surgical removal of fibromas and adjacent plantar fascia is often done, although recurrence is common. This review aims to provide a broad overview of the clinical features of this disease as well as the current treatment strategies being employed in the management of this condition.

1 April 2023 in JBJS Reviews
Verified
Journal Article
Closed access
JCJeremy D. Carroll
Jeremy D. Carroll
JYJoseph R. Young
Joseph R. Young
BMBenjamin Villacres Mori
Benjamin Villacres Mori
RGRohan Gheewala
Rohan Gheewala
ALAkshay Lakra
Akshay Lakra
MDMatthew R. DiCaprio
Matthew R. DiCaprio
» Obesity, defined as body mass index (BMI) ≥30, is a serious public health concern associated with an increased incidence of stroke, diabetes, mental illness, and cardiovascular disease resulting in numerous preventable deaths yearly. » From 1999 through 2018, the age-adjusted prevalence of morbid obesity (BMI ≥40) in US adults aged 20 years and older has risen steadily from 4.7% to 9.2%, with other estimates showing that most of the patients undergoing hip and knee replacement by 2029 will be obese (BMI ≥30) or morbidly obese (BMI ≥40). » In patients undergoing total joint arthroplasty (TJA), morbid obesity (BMI ≥40) is associated with an increased risk of perioperative complications, including prosthetic joint infection and mechanical failure necessitating aseptic revision. » The current literature on the role that bariatric weight loss surgery before TJA has on improving surgical outcomes is split and referral to a bariatric surgeon should be a shared-decision between patient and surgeon on a case-by-case basis. » Despite the increased risk profile of TJA in the morbidly obese cohort, these patients consistently show improvement in pain and physical function postoperatively that should be considered when deciding for or against surgery.

3 July 2021 in Current Reviews in Musculoskeletal Medicine
Verified
Journal Article
Closed access
PDF file
KVKhushdeep S. Vig
Khushdeep S. Vig
CACurtis Adams
Curtis Adams
JYJoseph R. Young
Joseph R. Young
EPEric Perloff
Eric Perloff
COCasey M. O’connor
Casey M. O’connor
CCCory M. Czajka
Cory M. Czajka

8 May 2020 in Current Reviews in Musculoskeletal Medicine
Verified
Journal Article
Closed access
PDF file
COCasey M. O’connor
Casey M. O’connor
AAAfshin A. Anoushiravani
Afshin A. Anoushiravani
CACurtis Adams
Curtis Adams
JYJoe R. Young
Joe R. Young
KRKyle Richardson
Kyle Richardson
ARAndrew J. Rosenbaum
Andrew J. Rosenbaum

1 September 2020 in JBJS Reviews
Verified
Journal Article
Closed access
JYJoseph R. Young
Joseph R. Young
MAMatthew J. Anderson
Matthew J. Anderson
COCasey M. O’cOnnor
Casey M. O’cOnnor
JKJillian M. Kazley
Jillian M. Kazley
AMAbigail L. Mantica
Abigail L. Mantica
VDVivek Dutt
Vivek Dutt
» Developmental dysplasia of the hip (DDH) encompasses a wide spectrum of hip disorders, including neonatal instability, acetabular dysplasia, hip subluxation, and frank dislocation of the hip. It is a common disorder, with a reported incidence of between 0.1% and >10% of live births. » Coordinated, interdisciplinary care is important to achieving successful outcomes. This starts with accurate assessment of risk factors in the prenatal period, thorough clinical examination by the primary care provider at all well-child visits, and early referral to a pediatric orthopaedic surgeon for prompt diagnosis and treatment. » Early diagnosis and prompt treatment is critical for an excellent outcome. Ongoing, open communication between clinicians is essential for the effective coordination of care. » Treatment options vary depending on the age of presentation. A Pavlik harness (dynamic hip abduction orthosis) is used for children up to 6 months of age. A more rigid abduction orthosis may be used if treatment with a Pavlik harness is unsuccessful, with a closed reduction and spica cast being the next step if needed for children up to 18 months of age. Finally, open reduction with possible concomitant femoral and/or pelvic osteotomies is the surgical option in an older child, when necessary. In general, the later the child is diagnosed with and treated for DDH, the greater the risk of a nonoptimal outcome. » Depending on the severity of the condition, children with DDH may need to be followed closely until skeletal maturity so as not to miss the diagnosis of asymptomatic residual hip dysplasia, which can predispose patients to early hip arthritis.